BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | stella

Learn Data For Researchers Find trials matched to me

Learn Data For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | stella

Back to Rheumatoid Arthritis (RA) trials

Opening soon

Plain-English translation of NCT07729995 on ClinicalTrials.gov ↗ · Source last updated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

United States

Boston Children's Hospital, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Luminary Therapeutics

Enrollment target

~94 participants

Started

October 2026

Primary completion

March 2030

Age range

16 Years – 75 Years

Last updated on clinicaltrials.gov in July 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Susan Prockop, MD

Luminary Therapeutics

View full record on ClinicalTrials.gov

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.